JAZZ
Jazz Pharmaceuticals plc
Stock
$235.67+2.66 (+1.14%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.7B | $1.4B | $1.4B | $1.1B | $1.3B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | $288M | $250M | $152M | $59M | −$16M |
| Capital expenditures | $70M | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $9.7M | $36M | $36M | $10.0M | $6.0M | $1.3M | $731K | $53K |
| Free cash flow | $1.6B | $1.3B | $1.4B | $1.1B | $1.2B | $751M | $885M | $736M | $779M | $664M | $583M | $496M | $371M | $278M | $244M | $150M | $58M | −$16M |
| Stock-based compensation | $307M | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | $45M | $23M | $21M | $8.2M | $6.0M |
| Buybacks | — | $125M | $311M | $270M | $54K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | $136M | $0 | $0 | — | — |
| Free cash flow margin | 34.6% | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% | 37.4% | 34.1% | 41.2% | 41.0% | 39.2% | 37.4% | 31.7% | 31.9% | 41.6% | 55.2% | 33.5% | −12.4% |